Literature DB >> 34734365

Potential novel imaging targets of inflammation in cardiac sarcoidosis.

Jakob Park1, Bryan D Young2, Edward J Miller3.   

Abstract

Cardiac sarcoidosis (CS) is an inflammatory disease with high morbidity and mortality, with a pathognomonic feature of non-caseating granulomatous inflammation. While 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a well-established modality to image inflammation and diagnose CS, there are limitations to its specificity and reproducibility. Imaging focused on the molecular processes of inflammation including the receptors and cellular microenvironments present in sarcoid granulomas provides opportunities to improve upon FDG-PET imaging for CS. This review will highlight the current limitations of FDG-PET imaging for CS while discussing emerging new nuclear imaging molecular targets for the imaging of cardiac sarcoidosis.
© 2021. American Society of Nuclear Cardiology.

Entities:  

Keywords:  Tracer development; inflammation; sarcoid heart disease

Mesh:

Substances:

Year:  2021        PMID: 34734365     DOI: 10.1007/s12350-021-02838-w

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   3.872


  114 in total

1.  Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation.

Authors:  Michael T Osborne; Edward A Hulten; Venkatesh L Murthy; Hicham Skali; Viviany R Taqueti; Sharmila Dorbala; Marcelo F DiCarli; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2016-06-08       Impact factor: 5.952

2.  Repeatability and Optimization of FDG Positron Emission Tomography for Evaluation of Cardiac Sarcoidosis.

Authors:  Raza M Alvi; Bryan D Young; Zartashia Shahab; Hongyi Pan; Julia Winkler; Erica Herzog; Edward J Miller
Journal:  JACC Cardiovasc Imaging       Date:  2019-03-04

3.  Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring.

Authors:  Panithaya Chareonthaitawee; Rob S Beanlands; Wengen Chen; Sharmila Dorbala; Edward J Miller; Venkatesh L Murthy; David H Birnie; Edward S Chen; Leslie T Cooper; Roderick H Tung; Eric S White; Salvador Borges-Neto; Marcelo F Di Carli; Robert J Gropler; Terrence D Ruddy; Thomas H Schindler; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2017-10       Impact factor: 5.952

4.  Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis.

Authors:  Azadeh Ahmadian; Ashley Brogan; Jeffrey Berman; Aaron L Sverdlov; Gustavo Mercier; Michael Mazzini; Praveen Govender; Frederick L Ruberg; Edward J Miller
Journal:  J Nucl Cardiol       Date:  2014-05-31       Impact factor: 5.952

5.  A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology.

Authors:  Riemer H J A Slart; Andor W J M Glaudemans; Patrizio Lancellotti; Fabien Hyafil; Ron Blankstein; Ronald G Schwartz; Wael A Jaber; Raymond Russell; Alessia Gimelli; François Rouzet; Marcus Hacker; Olivier Gheysens; Sven Plein; Edward J Miller; Sharmila Dorbala; Erwan Donal
Journal:  J Nucl Cardiol       Date:  2018-02       Impact factor: 5.952

6.  Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis.

Authors:  Nobuhiro Tahara; Atsuko Tahara; Yoshikazu Nitta; Norihiro Kodama; Minori Mizoguchi; Hayato Kaida; Kenkichi Baba; Masatoshi Ishibashi; Naofumi Hayabuchi; Jagat Narula; Tsutomu Imaizumi
Journal:  JACC Cardiovasc Imaging       Date:  2010-12

7.  Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis.

Authors:  Wataru Okumura; Tsutomu Iwasaki; Takuji Toyama; Tatsuya Iso; Masashi Arai; Noboru Oriuchi; Keigo Endo; Tomoyuki Yokoyama; Tadashi Suzuki; Masahiko Kurabayashi
Journal:  J Nucl Med       Date:  2004-12       Impact factor: 10.057

8.  FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models.

Authors:  T Mochizuki; E Tsukamoto; Y Kuge; K Kanegae; S Zhao; K Hikosaka; M Hosokawa; M Kohanawa; N Tamaki
Journal:  J Nucl Med       Date:  2001-10       Impact factor: 10.057

9.  Additional Heparin Preadministration Improves Cardiac Glucose Metabolism Suppression over Low-Carbohydrate Diet Alone in ¹⁸F-FDG PET Imaging.

Authors:  Asbjørn M Scholtens; Hein J Verberne; Ricardo P J Budde; Marnix G E H Lam
Journal:  J Nucl Med       Date:  2015-12-10       Impact factor: 10.057

10.  Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations.

Authors:  A Perry; F Vuitch
Journal:  Arch Pathol Lab Med       Date:  1995-02       Impact factor: 5.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.